C4391024 - An Interventional, Open-Label, Randomized, Multicenter Phase 3 Study of PF-07220060 Plus Letrozole Compared to CDK4/6 Inhibitor Plus Letrozole in Participants Over 18 Years of Age With Hormone Receptor (HR)-Positive, HER2-Negative Advanced/Metastatic Breast Cancer who Have not Received any Prior Systemic Anticancer Treatment for Advanced/Metastatic Disease (FourLight-3)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512925-95-00

Acronym

C4391024

Enrollment

422

Registered

2025-04-08

Start date

2025-05-16

Completion date

Unknown

Last updated

2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced/Metastatic Breast Cancer

Brief summary

• PFS by blinded independent central review (BICR)

Detailed description

• OS

Interventions

DRUGLETROZOLE

DRUGIBRANCE 75 mg hard capsules

DRUGRIBOCICLIB

DRUGABEMACICLIB

DRUGIBRANCE 100 mg hard capsules

DRUGIBRANCE 125 mg hard capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
• PFS by blinded independent central review (BICR)	—

Secondary

Measure	Time frame
• OS	—

Countries

Belgium, Bulgaria, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Poland, Slovakia, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026